NCT06501183View on ClinicalTrials.gov

Anti-CDH17 CAR-T Cell Injection in Patients With CDH17-positive Advanced Malignant Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

July 8, 2024

Primary Completion Date

May 30, 2025

Study Completion Date

May 30, 2026

Conditions
CDH17-positive Advanced Malignant Solid Tumors
Interventions
BIOLOGICAL

Anti-CDH17 CAR-T cells

Anti-CDH17 CAR-T cell injection will be administered intravenously after lymphodepleting.

Trial Locations (1)

Unknown

RECRUITING

Shanghai Pudong hospital, Shanghai

All Listed Sponsors
collaborator

UTC Therapeutics Inc.

INDUSTRY

lead

Shanghai Pudong Hospital

OTHER